Pharma Marketing Network

Ed and his wife have just sat down to a table at a fancy Italian restaurant. The waiter comes over and asks them a...

According to the Acomplia Report, "It's now official. If diet drug Acomplia (rimonabant) is ultimately approved for sale in the United States, the prescription...

A recent article in the Boston Globe about pharmaceutical companies "pitching empathy" to doctors focused on an exhibit at the American Academy of Neurology...

Peter Rost is at it again! He now reveals how AstraZeneca plans to "gain access and enhance selling opportunities for Arimidex, Abraxane, and Faslodex...

Exubera -- Pfizer's new insulin delivery system for the treatment of diabetes -- has not been well-received so far by physicians and payers (see...

A discussion with Fard Johnmar of Envision Solutions focused on his company's recent survey about American opinion of pharma-non-profit cause alliances and the implication for the future of pharma cause marketing.

This commentary takes a look at some

Mobile devices -- especially cell phones -- are becoming ubiquitous in the U.S. How can pharmaceutical companies use this technology for consumer acquisition and retention? To get some ideas, we interviewed Robert Flynn, President of Pulse Media Response, LLC, and summarize that discussion in this article.

There are few new blockbusters on the horizon and many profitable drugs are coming off patent. If pharmaceutical marketers want seats at the table, then they must show how marketing can contribute to long-term company financial performance.

This article by Dr. Jane Chin of the Medical Science Liaison Institute, offers suggestions for MSL metrics based on results of a consensus survey.